论文部分内容阅读
[目的]探讨CHOP+平阳霉素(PYM)方案与IMEP方案治疗鼻型NK/T细胞淋巴瘤的的疗效与安全性。[方法]85例鼻型NK/T细胞淋巴瘤患者分为试验组(CHOP+PYM方案组)(n=42)和对照组(IMEP方案组)(n=43),比较两组的有效率、毒副反应及生存率。[结果]试验组42例中,CR29例,PR2例,有效率为73.81%;对照组43例中,CR30例,PR3例,有效率76.75%,两组有效率比较无统计学差异(P>0.05)。两组最常见的毒副反应均为血液系统毒性、胃肠道反应和脱发。试验组和对照组Ⅲ～Ⅳ度白细胞减少发生率分别为26.19%和53.49%(P<0.05)。Ⅰ～Ⅱ度出血性膀胱炎发生率分别为9.52%和27.91%(P<0.05),其他毒副反应两组比较无统计学差异(P>0.05)。试验组中位总生存期(MST)为25.56个月,1年生存率为83.33%,2年生存率为42.86%。对照组中位总生存期为26.37个月,1年生存率为79.07%,2年生存率为39.54%,两组1年、2年生存率比较无统计学差异(P>0.05)。[结论]与IMEP方案相比,CHOP+PYM方案有效率、近期生存率与其相近,但血液学毒副反应较低。CHOP+PYM值得临床进一步研究。
[Objective] To investigate the efficacy and safety of CHOP + PYM and IMEP in the treatment of nasal NK / T cell lymphoma. [Method] Eighty-five patients with nasal NK / T cell lymphoma were divided into experimental group (CHOP + PYM group) (n = 42) and control group (IMEP group) , Toxicity and survival rate. [Results] Among the 42 patients in trial group, CR29 cases and PR2 cases had an effective rate of 73.81%. In the control group, CR30 cases and PR3 cases showed an effective rate of 76.75%. There was no significant difference between the two groups (P> 0.05). The most common adverse reactions in both groups were hematologic toxicity, gastrointestinal reactions and alopecia. The incidence of grade Ⅲ ~ Ⅳ leukopenia in the experimental group and control group were 26.19% and 53.49%, respectively (P <0.05). The incidence of grade Ⅱ ~ Ⅱ hemorrhagic cystitis were 9.52% and 27.91% respectively (P <0.05). There was no significant difference in other toxic and side effects between the two groups (P> 0.05). The median overall survival (MST) of the experimental group was 25.56 months, the 1-year survival rate was 83.33%, and the 2-year survival rate was 42.86%. The median overall survival of the control group was 26.37 months, the 1-year survival rate was 79.07% and the 2-year survival rate was 39.54%. There was no significant difference in the 1-year and 2-year survival rates between the two groups (P> 0.05). [Conclusion] Compared with IMEP, CHOP + PYM is effective and has similar short-term survival rate, but hematologic toxicity is low. CHOP + PYM deserves clinical further study.